Dr. Fatih M. Uckun MD, PhD earned his doctoral degrees at University of Heidelberg and completed his residency training in pediatrics fellowship training in hematology/oncology/stem cell transplantation as well as postdoctoral research training in immunology at the University of Minnesota. After serving at the University of Minnesota as a Professor of Pediatrics Therapeutic Radiology, Pharmacology and Director of the Biotherapy Institute. He is the Leader of the Developmental Therapeutics Program at the Children′s Center for Cancer and Blood Diseases and directs an NIH funded Nanomedicine RD Program at the Children′s Hospital Los Angeles Dr. Uckun has more than 20 years of professional experience in developmental therapeutics and biopharmaceuticals. He served as the Editor-in-Chief of Leukemia Lymphoma and as a member of several editorial boards and NIH review panels. He received numerous awards including the Stohlman Memorial Award of the Leukemia Society of America.

Translational Research aimed at identifying new molecular targets in treatment of cancer and inflammatory disorders, Targeted Nanoparticles, Biopharmaceuticals, Molecular Epidemiology of Cancer, Chemoprevention of Cancer, Epigenetic regulation of cancer growth, Innate Immunity, Signal transduction pathways.

Dr. Ljubimova received her medical degree from Kiev Medical School in Ukraine and her doctoral degree from the Ukraine Academy of Sciences. She completed her postdoctoral training at Cedars-Sinai Medical Center. Her studies have been published in numerous peerreviewed publications including the American Journal of Pathology and International Journal of Oncology. Her research has received funding from Arrogene and the Air Pollution Foundation.

Primary research interests involve methods to block human glioma growth, brain tumor prevention treatments and the effects of air pollution on the brain.

He did a postdoctoral research at Department of Chemistry, the University of Florida, after earning his PhD in Chemistry Chinese Academy of Sciences. He has authored about 100 research publications that include 5 book chapters review articles.

Micro/nanocantilever chem/biosensors, Nanomechanical drug screening technology, Cancer detection and treatment, Advanced materials, Combinatory chemistry, host-guest interaction, molecular recognition, Organic and organometallic photochemistry, electron and energy transfer processes, conjugated polymers, fluorescent sensors.

Professor Jin-Woo Kim has received his PhD in biological engineering from Texas AM University College Station in 1998 Currently he is a director of the Bio/Nano Technology Laboratory and a Professor of Biological Engineering, and Biomedical Engineering at the Department of Biological and Agricultural Engineering Biomedical Engineering Graduate Program, Cell and Molecular Biology Graduate Program and Institute for Nanoscale Materials Science and Engineering of the University of Arkansas, Fayetteville. His research expertise spans interdisciplinary fields of biological engineering biomedical engineering biology chemistry and nanotechnology. He has been serving as an editorial member of the reputed journals like Nanomedicine 2005-2008 and Journal of Biological Engineering 2006 at present.

Aqueous-phase self-organization of nanomaterials and their biological and biomedical applications, in particular bio-driven nanostructure self-assembly, nanoscale bio/abio interfacing technology, nanoparticle-based disease diagnostics and therapeutics, nanobiotechnology for hybrid device development and nucleic acid technology for molecular computation.

He received his PhD in Marine Biology from Scripps Institution of Oceanography, University of California at San Diego. He completed his Postdoctoral Fellowship in the Department of Cell Biology, Baylor College of Medicine, Houston, Texas. Dr. Perry joined the UTSA faculty in 2006 from Case Western Reserve University where he was Professor of Pathology and Neurosciences and Chair of the Department of Pathology. He is also distinguished as one of the top 20 Alzheimer′s disease researchers with over 800 publications, one of the top 100 most-cited scientists in Neuroscience & Behavior and one of the top 25 scientists in Free Radical research . He currently serves as and President for the American Association of Neuropathologists. He is on the editorial board of over 60 journals including American Journal of Pathology and Journal of Biological Chemistry, and is Editor-in-Chief of Journal of Alzheimer Disease.

 The mechanism for RNA-based redox metal binding,  the consequences of RNA oxidation on protein synthesis rate and fidelity, the role of redox active metals in mediating prooxidant and antioxidant properties, the signal transduction pathways altered in Alzheimer′s disease that allow neurons to evade apoptosis, mechanism of phosphorylation control of oxidative damage to neurofilament proteins.

Mark A. Smith is professor of pathology at Case Western Reserve University in Cleveland, Ohio where he also serves as Director of Basic Science Research at the University Memory and Aging Center. Dr. Smith serves as Editorin Chief of the Journal of Alzheimer′s  Disease and also sits on the Editorial Board of over 20 leading journals including Science Translational Medicine, The Journal of Neurochemistry and The American Journal of Pathology. He is recognized in the field of Alzheimer′s disease research particularly for his work on oxidative stress mitochondria dysfunction and cell cycle reentry and, with a hindex of 73 and over 800 peerreview articles and reviews that have received over 21000 citations, he is distinguished as one of the top Alzheimer′s disease researchers in the world, one of the top 100 mostcited scientists in Neuroscience Behavior and one of the top 25 scientists in free radical research.

Fundamental metabolic alterations, Homeostatic dysregulation of transition metals, Signal transduction alterations, Inappropriate re-entry into the cell cycle.

Stephen J Beebe received a BS in Zoology from Ohio University Athens 1970 and a PhD 1982 in medical sciences pharmacologyand biochemistry from the Medical College of Ohio, Toledo. He did postdoctoral studies 1982–1987 in the Department of Molecular Physiology and Biophysics at the Howard Hughes Medical Institute,Vanderbilt Nashville, Tenn, before serving as a Fulbright Scholar and Norwegian Marshall Scholar in Institute for Medical Biochemistry 300 S. J. Beebe and K. H. Schoenbach 2005:4 2005 and the National Hospital in Oslo Norway (1987–1988). Dr. Beebe has received various honors including Outstanding Senior Visiting Scientist from the Norwegian Cancer Society while in Bergen Norway (1997–1999), the Iwao Yasuda Award by the Society for Physical Regulation in Biology and Medicine, and the Martin Black Award from the Institute of Physics and Engineering in Medicine.

His research has focused on signal transduction mechanisms and structure-function studies of protein kinases using multiple disciplinary approaches utilizing pharmacology, biochemistry, physiology,molecular and cellular biology, and physics. Recently, he has helped develop the potential use of high-intensity nanosecond pulsed electric fields as a novel stimulus to regulate intracellular signal transduction.

Rajendra G. Mehta was previously a Research Associate, Department of Biochemistry, University of Rochester Cancer Center Rochester, New York. He obtained his BSc 1966 and M.Sc 1968, Zoology/Cell Biology, Gujarat University, Ahmedabad, India and PhD 1974, Life Sciences Cell Biology, University of Nebraska, Lincoln, Nebraska. He has over 30 years of research experience. He has authored about 146 Peer reviewed Papers, 29 Review Chapters in Books, 135 Abstracts and 2 patents. He got International Cancer Research Technology Transfer ICRETT Award by the International Union Against Cancer, Geneva, Switzerland, to conduct research at the First Department of Medicine, University of Tokyo, Tokyo,Japan, 1985.

Neoplasms, Antineoplastic agents, Combination drug therapy, Preclinical drug evaluation, Molecular structure.

He obtained his BS from Rutgers University 1977 and MS degrees from NYU, Institute of Environmental Medicine 1980 and PhD 1994 from Eastern Virginia Medical School.

Nanobiology of Aging, Nanotechnology, Traumatic Brain Injury, Brain Inflammation.

He got his BA in English and Neuroscience from Williams College Williamstown MA1993-1997 and MD 1998-2002 from Mount Sinai School of Medicine New York NY. He is a Director of the Pediatric Bone and Soft Tissue Sarcoma Program at UCLA . He is a Peer reviewer for 9 Journals. He is authored about 15 Poster Presentations 14 Peer-reviewed Publications 49 lectures and presentations. He got Medical Student Research Award Fellow Research Award UCLA STAR Award Today  and Tomorrow  Children Fund Award Patient Choice Award and Ontime Physician Award.

Nanotechnology: developing nanoparticles to specifically target sarcomas and deliver cytotoxic chemotherapy.  As a member and institutional principle investigator for the Sarcoma Alliance Research Through Collaboration (SARC), Federman leads an experienced pediatric sarcoma clinical research team with an emphasis towards studying promising new agents in children with very aggressive and often fatal metastatic and refractory bone and soft tissue cancers.

Dr. Rastogi finished his Internal Medicine residency and Nephrology fellowship at the David Geffen School of Medicine at UCLA . He also has a doctoral degree in Pharmacology which he completed under the mentorship of Nobel Laureate Louis Ignarro also at UCLA . His dissertation was on the role of nitric oxide in inflammation and various factors modulating high output nitric oxide production. Dr. Rastogi is the Director of the UCLA Dialysis Program. He oversees the clinical operations of the dialysis unit including many clinical studies. He also oversees the Multidisciplinary Chronic Kidney Disease Program at UCLA. Dr. Rastogi has also been deeply involved in medical education and is the CoDirector of the Nephrology Fellowship Training Program and is also actively involved in Clinical Pharmacology.

Chronic kidney disease and hypertension.

Marianna Foldvari, D Pharm,  PhD served as Scientific Advisor of Helix Biopharma Corp. Dr. Foldvari founded PharmaDerm Laboratories Ltd; in 1991. She serves as the Associate Director, Research and Graduate Studies at the University of  Waterloo′s School of Pharmacy. Dr. Foldvari served as Associate Dean of Research and Graduate Affairs in the College of Pharmacy and Nutrition University of Saskatchewan. She serves as a Director of PharmaDerm Laboratories Ltd.She serves on the Editorial board of Current Drug Delivery and the International Journal of Compounding In 2006. Dr. Foldvari moved to the School of Pharmacy University of Waterloo where she is a Professor of Pharmaceutical Sciences and part of a new team developing a coop pharmacy program the first in Canada. She is a Professor of Pharmaceutical Sciences at the University of Saskatchewan Since 1989. she was an Assistant Professor at the College of Pharmacy and Nutrition University of Saskatchewan. She is well known as a lsquo;venturesome Professorrsquo, in technology transfer. Dr. Foldvari has authored some 100 papers and delivered 70 conference presentations She is the inventor on 14 patents or patent applications. She has over 150 publications.

Cutaneous gene delivery systems, Dermal and transdermal protein delivery systems, Topical delivery systems for small molecules, Vaccine-based delivery systems, Biomaterial research for delivery system design and fabrication.

Rutledge Ellis-Behnke is Professor at the University of Heidelberg Mannheim Faculty of Medicine, where he is the Director of the Nanomedicine Translational Think Tank. In addition he is Research Affiliate in the Brain and Cognitive Sciences department at the Massachusetts Institute of Technology. Previously he was Associate Director of the Technology Transfer Office and Associate Professor in the Faculty of Medicine at the University of Hong Kong. He received his PhD from MIT in Neuroscience BSc from Rutgers University and graduated from Harvard Business School’s International Senior Manager’s Program AMP/ISMP. Prior to returning to school to pursue his PhD EllisBehnke held various management positions including Senior Vice President of Huntingdon a public company for testing and consulting services and Cofounder/CEO in 1995 of one of the first internet companies to do online commerce.

His primary research interest is using nanotechnology to reconnect the disconnected parts of the brain in order to restore function.

Dr. Yasuhiko Onishi has received his PhD DSc in Hiroshima University at 1979 he worked as full professor in Nippon Bunri University during the period from 2000 to 2002 Currently he has founded Ryujyu science corporation. He has successfully completed his Administrative responsibilities as CEO. He is a member of the Japanese Society of Gene Design and Delivery and the Society of Polymer Science Japan.

Non-viral polyfection reagent Poly-ion complex Nanotechnology.

Dr. Rogério Gaspar, obtained his PhD in Pharmaceutical Sciences from the Catholic University of Louvain Belgium in 1991, after a graduation as pharmacist from the University of Coimbra Portugal. Currently he is a Full Professor at the Faculty of Pharmacy University of Lisbon. There he also acts as the coordinator of the Nanomedicine Drug Delivery Systems research group within the Research Institute for Medicines and Pharmaceutical Sciences iMedUL which he cofounded in 2007.

The development of new therapeutic strategies using liposomes, polymeric biodegradable nanoparticles, and polymer therapeutics. His main focus in research is currently oriented towards cytosolic delivery of nucleic acids and use of targeted delivery systems for combination therapy in cancer.

Roukos DH, Ioannina University, Greece. Dimitrios Roukos, MD (Athens University, Greece), PhD (J.W.Goethe University, Frankfurt a.M., Germany), has moved his scientific interest after 25 years of reductionist medicine to network biology-based systems medicine. Assessing the clinical limitations of current traditional medicine to cure in the future incurable diseases such as cancer, has focused over the last 5 years on human cancer genome both structural variation and functional heterogeneity. His emerging goal is to understand how inherited and somatic mutations, epigenome, transcriptome and interactome abnormalities change chromatin dynamic states and gene expression. Emerging evidence suggests that this gene dysfunction and deregulation of cell signalling pathways drive tumorigenesis and metastasis. His ultimate goal is to approach next-generation anticancer drugs and biomarkers to future achievement of personalized medicine and network biology-based managment of cancer.Publication metrics: > 200 papers with ~ 5,000 citations (h=55) in PubMed, ISI, Scopus and current editor of two eBooks on personalized management of cancer and cancer genome heterogeneity-based treatment of cancer. Currently is key evaluator in European Commission (FP7 Systems Medicine area) and French National Research Agency (22 billion euros) participating in experts panel meeting in Brussels and Paris (end 2011) for the selection of best projects. He is leader of Translational Research in European Union Network of Excellence (EUNE) for gastric cancer and Personalized Cancer Genomic Medicine, Biobank in Ioannina University (Greece). He has been invited speaker and consensus member in multiple International Cancer Meetings. He serves as Editor-in-Chief, Associate Editor and Editorial board member in 20 influential journals.

Assessing limitations of conventional reductionist medicine, he have shifted to multi-scale genes, proteins, molecules, DNA, and RNA interactions in physical and functional networks. Revolutionary NGS technologies provide mow sequencing of DNA (whole genome, exome), transcriptome (RNA-seq, Chip-seq), epigenome (BS-seq) and also along with novel techniques (living cells imaging and computational models) also deeper insights into the grand challenge of interactome (multidimensional spatiotemporal protein-protein interactions). Integrating all these experimental data (omics, living-cells imaging, 3D-genome resolution and intra- and inter-cellular differentiation mapping) and large-scale clinical data into computational models, deep understanding of a personal genome code-lifestyle interactions network is beginning to be shaped. The perspectives of future medicine based on clinical genome and systems science are now rationally excellent for revolutionizing healthcare.

Damiao Pergentino de Sousa completed his graduation in Pharmacy in 1995 and obtained his Master  degree in Natural Products (Pharmacology and Chemistry) in 1998, both from the Federal University of Paraíba. He did his PhD studies in Sciences (Area: Organic Chemistry) in 2004 from the Federal University of São Carlos, Brazil. He is currently a professor at the Federal University of Sergipe. His current research areas are Medicinal Chemistry, Structural Modification of Terpenes, Chemistry of Natural Products, and Preparation of Bioactive Substances from Secondary Metabolites. He has published 59 articles in international refereed journals and 9 in Brazilian journals, and has given 158 presentations on scientific studies at several conferences. He is a reviewer of 15 journals.

Design, Synthesis and evaluation of bioactive compounds, Chemistry of Natural Products, Psychoactive Drugs, Essential Oils, Medicinal Chemistry.
 

Dinorah Gambino obtained her Pharmaceutical Chemist degree and PhD in Inorganic Chemistry at the Faculty of Chemistry, Universidad de la República, Uruguay. She appointed an initial position at Faculty of Chemistry in 1979 and is currently Full Professor of Inorganic Chemistry in this institution since 2010. She is reviewer for several journals on Inorganic Chemistry, Bioinorganic Chemistry, Medicinal Chemistry and Biology and was guest editor for hot topic issues Metals in Medicinal Chemistry (Minireviews in Medicinal Chemistry, 2004) and Advances and current perspectives in Medicinal Inorganic Chemistry (Current Medicinal Chemistry, 2010).
Her research interests are centered on the chemistry and applications of metals in medicine and the design and study of mechanism of action of novel metal-based potential therapeutic agents, mainly for the treatment of diseases of high incidence in America: neglected parasitic diseases (Chagas disease or American Trypanosomiasis and Leishmaniasis), tuberculosis and cancer.
 

Development of metal complexes for the therapy of cancer and parasitic diseases (mainly Chagas disease and Leishmaniasis).
Vanadium complexes as insulin-mimetic and antitumor agents.
Studies of the interaction of bioactive complexes with biomolecules like DNA and proteins.
Insight into the mechanism of action of metal-based potential drugs.
Rhenium, Technetium and Gallium complexes with radiopharmaceutical potentiality.
Metal complexes for the treatment of tuberculosis.

She got her PhD from Arizona State University, Tempe, AZ, 1993 Associate Editor for IEEE Trans. Power Delivery Reviewer- a number of journals and conferences in bio and electrical engineeringNIH Proposal reviewer, NSF proposals reviewer Publications - Over 130 including journal, conference, book chapters, and IEEE Stds Member, Oncological Sciences Center, Purdue University President, Electrostatics Society of America – 2009 2011 Chair, IEEE International Conference on Electrical Insulation and Dielectric Phenomena has BioDielectrics session – 2010 2011Vice Chair/Treasurer, Workshop on BioDielectrics, entitled, “High Field Effects and Fast responses in biosystems” 2003.

Electro-chemo-therapy, Electro-gene-therapy, Electric field simulation of biological systems under ac/dc electroporation, Modeling/simulation study of biological systems, Laser optoinjection of molecules into cells, Ethics in medical field, Medical Electronics, Pulse generator – design and development for biological studies, Energy and environment, Higher/engineering education.

He obtained his BS honors and MS degrees in Mechanical Engineering, Chonbuk National University, South Korea and a Post Doctorate Fellow at Nano Institute, University of Cincinnati, Ohio did PhD; in Mechanical Engineering from University of Cincinnati at Ohio Post Doctorate Fellow at Nano Institute University of Cincinnati Ohio. He has authored about research publications that include book chapters, 55 review articles, and 1 patent, and he has given 19 meeting presentations and 13 invited seminars. Dr. Saha has edited 4 books, Reviewer for 6 journals.

Craniofacial and Orthopedic Applications (ES-I), Cardiovascular Devices (ES II), and Responsive Biosensors for Implants (ES III).

He obtained his BS Biology and MS degrees Organic Chemistry from Jammu University, Jammu & Kashmir State, India and PhD 1987 from All India Institute of Medical Sciences, New Delhi,India Immunology. He authored about 22 publications that inclide articles and reviews. He received All India Institute of Medical Sciences Fellowship Award India for PhD studies and Arthritis Investigator Award from Arthritis Foundation.

Cell and Molecular Immunology. My research interest encompasses the field of lymphocyte biology. A major goal of my research is to understand mechanisms underlying regulation of CD4+ T lymphocyte responses to protein antigens. Focus of research in my laboratory is on a set of glycosylphosphatidyl-inositol (GPI)-anchored proteins housed in membrane rafts. Membrane rafts are 10-200 nanometer size domains on the plasma membrane. These membrane entities are enriched in sphingolipids, cholesterol, GPI-anchored proteins and a variety of other signaling molecules. Membrane rafts have been implicated in spatiotemporal regulation of signaling from the membrane to cell interior. My laboratory has developed methods that will allow us to examine membrane rafts on single-nanodomain basis and investigate their spatial organization during CD4+ T cell activation and differentiation.

Dr. Raj Bawa is President of Bawa Biotechnology Consulting LLC a biotechnology and patent law firm founded in 2002 and based in Ashburn Virginia. He is a biochemist and microbiologist by training and is a registered patent agent licensed to practice before the US Patent and Trademark Office PTO. He serves as a Senior Scientist at SynerGene Therapeutics Inc in Potomac Maryland Currently he is the Principle Investigator of two National Cancer Institute/SBIR contracts titled "Targeted Nanocomplex for Early Detection of Lung Cancer" and "Targeted Nanocomplexed Iron Oxide for Early Detection with Concurrent Hyperthermia Treatment of Cancer." Previously he held various positions at the PTO, including Primary Examiner 6 years; Supervisory Patent Examiner acting; and Instructor at the US Patent Academ.

He specializes in all aspects of biotechnology, nanotechnology and pharmaceutical patent law, including prosecution, patent strategy, application drafting, prior art searching, freedom-to-operate searching and technology research opinions.

Dr. Kanwar is an immunologist and molecular biochemist with an international reputation in investigating fundamental and applied molecular aspects of cancer and chronic inflammation. He did his PhD from Post Graduate Institute of Medical Education and Research PGIMER Chandigarh, India. Before joining Deakin University in 2006, he was a Senior Scientist/Senior Research Fellow in the University of Auckland, Auckland, New Zealand. During the past decade his research both academic and commercial has centered on understanding the pathophysiological mechanisms and/or finding treatments for a variety of chronic inflammatory diseases and different types of cancer.

Nanotechnology based drug delivery of proteins/peptides, siRNA and miRNA to target cancer and chronic inflammation drug discovery for novel anticancer targets for cancer cell survival, death, arrest, and repair development of immunomodulatory and anti-inflammatory bioactives, proteins and peptides for neuroprotection development of complementary alternative medicine from the milk derived proteins including metal binding protein (Lactoferrin), and herbal preparation derived active components with a special focus on the treatment of solid tumours (colon and breast cancers).

Professor Michele Caraglia Currently is working as Associate Professor in Biohemistry at the Department of Biochemistry and Biophysics of the Second University of Naples. He is serving as an editorial member of several reputed journals like Current Cancer Drug Targets Cancer Biology and Therapy International Journal of Oncology Cell Biology International Recent Patents on Anticancer Drug Discovery. He is author of 2 international patents and is a member of American Association for Cancer Research and is in the Managing Board of the Italian Association for Cell Cultures AICC.

He has studied the escape mechanisms from the anti-proliferative and apoptotic effects induced by Interferon alpha in human cancer cells derived from epidermoid head and neck and lung cancers. He has found that these cells overcome the apoptosis through the induction of an EGF-Ras-dependent pathway that can be antagonized through the use of farnesyltransferase inhbitors potentiate the anti-cancer acitvity of the former in prostate and head and neck cancer cells.

Dr. Yan Zhang, an associate professor at College of Life Sciences, Peking University, was awarded PhD by McGill University, Department of Neurology and Neurosurgery in 2004. She was honored with “New Century Scientist” Fellowship in 2006. She is interested in the involvement of signal transduction pathway in Alzheimer’s disease, the mechanisms of neuronal cell death in various neurodegenerative diseases and the interaction of neuropeptide receptors and other excitatory/inhibitory receptors. Her research has resulted in publications in J Cell Biol, Cell Death Differ, J Neurosci, J Biol Chem, Prog Neurobiol, etc. and has been cited for more than 900 times.

Involvement of signal transduction pathway in Alzheimer’s disease, Mechanism of neuronal cell death in various neurodegenerative diseases, Interaction of neuropeptide receptors and other excitatory/inhibitory receptors.

He did a postdoctoral research at Department of Civil and Environmental Engineering Massachusetts Institute of Technology, Cambridge, MA, USA after earning his BS 2002 and PhD 2007 degrees from Tsinghua University. He received Ministry of Education of P R China Awards for Natural Science 2008. He has authored about research publications that include 24 review articles, 3 book chaptersand he has given 13 meeting presentations. As reviewers for following journals:Physics Review B, Journal of American Chemical Society, Journal of Mechanics and Physics of Solids, Nanotechnology, Colloid and Surfaces B, Journal of Computational and Theoretical Nanoscience, Acta Mechanica Solida etc.

Nanoenergetics and nanomachines, also the mechanics and physics of nano/bio-materials, through theoretical analysis and multi-scale / multi-physics simulation approaches.

He received his BS in Fine Chemical Engineering in 1998 and his MS in Applied Chemistry in 2001 from Kunming University of Science and Technology, and his PhD in Organic Chemistry in 2004 from Zhejiang University, where he was absorbed in the natural products chemistry, especially focusing on the part of medicinal activity, chromatography separation, and spectrometry investigation about the bio-active compounds. After graduating from school, he worked as lecture and associate professor in the Research Center of Siyuan Natural Pharmacy and Bio-toxicology, College of Life Science, Zhejiang University, China.

His work interest has focused on the chemistry and biology of natural products targeting breast cancer, including natural product discovery, breast cancer therapy and prevention.

Professor Nikolaos Labrou received his BSc degree in Chemistry with honors top 1 from the University of Patras Greece 19871991 and his PhD in Enzyme Biotechnology from the Agricultural University of Athens Greece in 1992-1996. He has conducted postdoctoral research in Leeds UK 19961998 and at Agricultural University of Athens 1998-2001. Dr. Labrou started his career as Assistant Professor at the Agricultural University of Athens 2002-2007. He is currently Associate Professor at the Agricultural University of Athens Department of Biotechnology. His research takes place where molecular enzymology chemistry and nanobiotechnology meet Within thelast 15 years Dr. Labrou published over 75 research articles in leading international journals 15 book chapters and established a strong global academic and industrial network.

Therapeutic Enzyme Engineering and Design (Rational enzyme design employing site-directed mutagenesis and computer-aided molecular modeling, Combinatorial design employing directed or random evolution approaches, Chemical modification, affinity labeling and inhibition analysis), Biotransformations and Nanobiotechnology, Downstream Processing of Therapeutic Enzymes and Proteins.

Dr. Sameh S Ali has received his PhD in Spin Chemistry and Magnetic Effects from Tohoku University Japan during the period of 1994-1997. Currently he is working as an Assistant Professor in the Departments of Medicine and Anesthesiology the University of California San Diego. He is also a member in the Institute of Engineering in Medicine in the University of California San Diego. He has successfully completed his Administrative responsibilities as a member in the organizing committees of international conferences on biomedical applications of nanotechnology.

Free Radical Biology and Medicine, Biomedical Applications of Fullerenes, Nanosensors and Bionanosensors.

Dr. Anita K Patlolla is a Research Assistant Professor in the Department of Biology/Environmental Science PhD Program at Jackson State University Jackson Mississippi USA. She earned her PhD in Environmental Sciences Toxicology Major concentration at Jackson State University Jackson MS USA Dr. Patlolla has published several research papers and chapters in the reputed international peerreviewed journals and books in the area of heavy metals and nanomaterials. Her articles are widely cited by other researchers in the field. She served as a reviewer for peer review journals in toxicology including Environmental Toxicology Toxicologic Pathology Basic Clinical Pharmacology Toxicology Prostaglandins Leukotrienes Essential Fatty Acids MidSouth Computational Biology and Bioinformatics and Hepatotoxicity.

Heavy metals and nanomaterials, Clinical Pharmacology Toxicology Prostaglandins, Leukotrienes & Essential Fatty Acids, MidSouth Computational Biology and Bioinformatics and Hepatotoxicity.

He received his PhD in Chemical Engineering from the University of Akron in 2004 Currently he is an Assistant Professor in the Department of Biomedical Engineering at Virginia Commonwealth University. He has authored over 20 research articles and book chapters. He is a member of Society for Biomaterials and Materials Research Society He is a recipient of NSF CAREER Award and Coulter Translational Research Award.

Dendrimers, Drug and gene delivery, Nanomedicine, Novel polymers.

Dr. Walker received his doctorate in Genetics Developmental Biology at West Virginia University followed by postgraduate work at Wake Forest University Health Sciences in the areas of molecular biology and proteomics. His initial faculty appointment was in the Department of Pediatrics Section on Medical Genetics at Wake Forest University Health Sciences. In this position he recruited families and carried out genetic association studies related to singlegene craniofacial disorders. From there he moved to the faculty in the Department of Physiology Pharmacology where he participated in studies examining the molecular basis for substance abuse using nonhuman primate animal models It is in this position that he was first introduced to microarray technology looking at gene expression at the "whole transcriptome" level.

Mental disorders/psychiatry/ps, Molecular biology, Immunology/allergy/inflammation, Model development, Genetics/genome.

Zhang received her undergraduate degree in engineering in 1996 at Tsinghua University in China. She earned a master′s degree in solid mechanics engineering in 2002, and a PhD in computational engineering and science in 2005 from the University of Texas at Austin. Zhang one of 17 award recipients nationwide, was selected by the Department of Defense′s DOD Office of Naval Research. Pittsburgh - Carnegie Mellon University′s Yongjie Jessica Zhang has received a three year 510000 Young Investigator Award for research excellence from the Office of Naval Research. She has authored about research publications that include 3 book chapters 33 review articles and he has given 60 meeting presentations and 26 invited seminars She organized/chaired 37 symposiums/sessions at national and international meetings she serves on the editorial board member and Reviewer for reputed journals.

Computational Geometry (especially mesh generation), Computer Graphics, Visualization, Finite Element Method, Isogeometric Analysis and their applications in Computational Biomedicine, Computational Biology and Engineering.

Yashveer Singh is an Assistant Research Professor at the Department of Pharmaceutics Ernest Mario School of Pharmacy Rutgers University. He received his PhD Chemistry under Prof Krishna Misra at the University of Allahabad India and didpostdoctoral studies with Profs. Santanu Bhattacharya at the Indian Institute of Science, Bangalore India; Eric Defrancq and Pascal Dumy at the Joseph Fourier University,Grenoble France; and Patrick J Sinko at the Rutgers University, New Brunswick USA. He has worked extensively on the development of synthetic strategies for oligonucleotide conjugates and ratiometric fluorescence sensors. He has published twentytwo research articles/reviews in peerreviewed journals two book chapters and two patents.

His current research efforts are focused on the design, fabrication, and evaluation of biomaterials for drugdelivery and targeting.

Moonsoo Jin graduated from Seoul National University with a BS in mechanical engineering Moonsoo Jin joined the Cornell faculty in 2006. His graduate research was recognized in 2003 with New Investigator Recognition Award by Orthopaedic Research Society. He completed his postdoctoral training in the CBR Institute for Biomedical Research Harvard Medical School.

Developing therapeutic antibodies against integrins, bacterial toxins, and viruses, Engineering diagnostic and therapeutic nanoparticles toward tumor detection & brain diagnostic nanoparticles, Modification of AAV capsid as a gene delivery vehicle.

Dr. Sivakumar Ganapathy did a postdoctoral research at the Chungbuk National University Cheongju South Korea. He obtained his PhD Botany Bharathidasan University Trichy India. He obtained his BS honors and MS degrees in Botany Ayya Nadar Janaki Ammal College Sivakasi India. He has authored about 25 research publications that include book chapters review articlesand he has given 7 meeting presentations.

Bioreactors Technology-Plant Root Culture Plant Metabolic Engineering Biopharmaceuticals Natural Products Molecular Chemistry.

Dr. Sungsoo Na is currently working as Assistant Professor in Department of Biomedical Engineering Purdue School of Engineering and Technology IUPUI.

The primary objective of our research group is to understand the biophysical mechanism by which cells sense and respond to specific physical stimuli in the environment, including dimensionality and rigidity of the extracellular matrix as well as mechanical force. As recent technology advances explosively in areas such as computing, molecular biology, nanotechnology, and microscopy, it is becoming increasingly recognized that the fundamental question of how cells function cannot be solved by focusing exclusively on individual genes and proteins; it also depends on mechanical cues, local microenvironment, and system level integration, which has collectively led to the fascinating new field: Mechanotransduction.

Dr. Simpson earned BS, MS and PhD degrees in Electrical Engineering from the University of Tennessee in 1983, 1987 and 1991respectively. At the time he received his PhD Simpson worked in RD at EGG Ortec and moved to the Scientific Staff of the Oak Ridge National Laboratory in 1992 where he initially worked on the design of highspeed, custom, analog, integrated circuits for collider physics experiments. Simpson is now a Distinguished Research Staff Member and Theme Leader in the ORNL Center for Nanophase Materials Sciences. Dr. Simpson began a joint faculty appointment with the University of Tennessee in 1993 first with the Electrical and Computer Engineering Department and now with the Materials Science and Engineering Department where he teaches nanobiosciences courses and performs research at the physicalbiological sciences boundary. Dr. Simpson has authored or coauthored 115 peer reviewed journal papers, holds 24 USA Patents and has presented numerous invited talks at conferences, workshops and symposia.

Complex systems at the boundaries between physical and life sciences, stochastic processes in complex nanoscale systems, nanostructured materials, bio-materials, synthetic biology.

He received MD from Hebrew University Hadassah School of Medicine, Jerusalem, Israel. He earned his Postdoctoral training at The Chaim Sheba Medical Center TelHashomer, Israel. He has published more than 400 peerreviewed papers and he has authored numerous review articles. He served as a member of several editorial boards. He received numerous awards.

Pulmonary inflammation targeted drug delivery Nanomedicine, Toxicity studies of nanostructures and heavy metals with biological systems with an emphasis on elucidating the relationship between the physical and chemical properties (e.g. size, shape, surface chemistry, composition, and aggregation) of heavy metals, nanostructures or nanoparticles with induction of toxic biological response. Dr. Patlolla extensively worked on the toxicokinetics, molecular mechanisms of toxicity and histopathology of heavy metals and nanomaterials in animal models. She has expertise in Genotoxicity Bioassay such as Chromosomal aberrations, Micronucleus Test and Comet assay.

Dr. Muro received her PhD in Molecular Biology from the University Autonoma of Madrid, Spain, in 1999. She had an extensive training in medical, biomolecular, and drug targeting research including fellowships and postdoctoral appointments in Spain, Canada, Denmark and the USA, where most recently she held a faculty appointment in the Department of Pharmacology in the School of Medicine of the University of Pennsylvania. Dr. Muro is currently an Assistant Professor in the University of Maryland at College Park, with a joint appointment in the Fischell Department of Bioengineering and the Institute for Bioscience and Biotechnology Research.

Mechanisms of endocytic vesicular transport: their role in physiology and disease, and their translational application for the controlled delivery of nano-scale therapeutics to precise targets at the sub-cellular level (targeting, intracellular drug delivery, endocytosis, cell culture, animal models, pharmacokinetics, microscope imaging).

Dr. Banerjee got his PhD in Molecular Biolgy from Howard University Cancer Center, DC Post Doctoral training at Yale University Medical School, Medical University of South Carolina and Rockefeller University in the laboratory of Nobel Laureate Dr. Gunter Blobel.He recieved predoctoral training award from NIH, PEW Foundation fellowship, Post doctoral National Research Scholarship Award NRSA from NIH.  He has recieved grants from NASA, NSF for his research and directs the laboratory of cell and molecular biology at his home institution. He is an emeritus member of American Association of Cancer Research, member of European Association of Cancer Research and member of Sigma Xi Scientific Research Society. He has published more than 35 peer reviewed papers and presented and given lectures on his work on cancer biology both in USA and abroad.

Cancer biology, Post apoptotic cell clearance, Cellular and molecular changes in microgravity.

Dr Igor F. Tsigelny has received his PhD in the National Academy of Sciences of Ukraine Currently he works as the Senior Program Project Scientist. at the University of California, San Diego. He serves as an editorinchief of the journal “Analytical Reports in International education”, as a series editor of the “Biotechnology series” of the International University Line Publishers. He has authored and edited three research books. He authored more than 180 research articles.

Bioinformatics, Structural biology, System biology, Genomics, Drug design, Biotechnology.

Dr. Chen has received his Doctor of Science degree in Biomedical engineering from Washington University in St. Louis in 2005. He has been selected as predoctoral fellow of American Heart Association between 2003 and 2004. Currently, he is working as an instructor in Division of Cardiology, Washington University School of Medicine. He has authored more than twenty research articles including invited review and book chapter. He is a regular reviewer for a number of reputed journals like Neuroimage and Magnetic Resonance in Medicine.

Magnetic resonance imaging, cardiovascular and retinal diseases, anti-angiogenesis therapy with nanoparticles.

Dr. Daniel Kelley received his PhD in Neuroscience from the University of Wisconsin Madison. Currently, he is a Fellow in the Medical Scientist Training Program MSTP at the University of Wisconsin School of Medicine and Public Health. He has completed his administrative role as national chair of the American Physician Scientist Association APSA Policy Committee. He has authored several articles in neuroscience, neuroimaging, neuropsychiatry, neurodevelopment, and nanomedicine. He is also an editorial member of the World Journal of Radiology and reviewer for numerous journals. He is a member of Phi Beta Kappa, MENSA, and the Society for Neuroscience, among others. In addition, he was honored as a Barry M. Goldwater Scholar and Howard Hughes Medical Institute HHMI Teaching Fello.

Neuroscience, Brain mapping in cognitive disorders: a multidisciplinary approach to learning the tools and applications of functional Neuroimaging.

He got his PhD from Polymer Science Technology Sri Krishnadevaraya University, Anantapur, India during the years 2001-2005. He working as a Associate Member of American Association for Cancer Research AACR, USA and Controlled release Society CRS, USA, American Association of Pharmaceutical Scientists AAPS, USA. He honoured Prof. A. Kameswara Rao’s Gold Medal for the Year 1999 and Editor for the BOOK eBOOK entitled “Recent Advances in Nanoscienceand Nanotechnology”. Several of his articles have been occupied top 25 articles in Elsevier Journals Respective journals. He serving as a Editorial Member for Journal of Biomaterials and Nanobiotechnology. Serve as a reviewer for several journals.

PEG-functinoalized Magnetic Nanoparticles for Drug Delivery and Magnetic Resonance Imaging Applications, Synthesis and Characterization of Hydrogel-Silver Nanoparticle-Curcumin Composites for Wound Dressing and Antibacterial Application, Scope of Nanotechnology in Ovarian Cancer, Rapamycin-Loaded Poly(N-Isopropylacrylamide)-Based Nanogels in Vascular Smooth Muscle Cells.

Joy received his MS and PhD in Physiology from the University of Calcultta, Calcutta, India. He did his first postdoctoral training in the Department of Pharmacology, University of Manitoba, Winnipeg, Canada and then in the Department of Medicine, Beth Israel Hospital, Harvard Medical School, Boston. After completion of postdoctoral training he started his career as a scientist in a biotech company in Boston. He received numerous awards in recognition of his novel research works. He published more than 30 full length papers in peerreviewed journals and wrote several book chapters. He is a reviewer of several scholarly journals.

His research interests include understanding the biology of different diseases, identify novel biotherapeutic targets, define biomarker strategy and develop antibody-protein therapeutics to treat diseases.

He received his Undergraduate, graduate, medical school from Dartmouth and Harvard University. He served as a Faculty member Neurosurgery at the following 1986-2001: University of California, Davis, Medical Center. He served as a Editor of Intraoperative Neuroprotection. Baltimore: Williams Wilkins, 1996. He authored about research publications that include Author/coauthor of over 30 book chapters, Author/coauthor of over 50 peerreviewed research articles, Presenter/copresenter of over 150 presentations at major national/international scientific meetings, 2 patents and CoDirector of International Conference on Neuroprotective Agents.

Carbon Nanotube-based Nanoelectrode Array for Deep Brain Stimulation.

Dr. Kerriann Greenhalgh received her PhD in Organic Chemistry at the University of South Florida during the period of August 2004 to December 2007. Currently, she is working as the Senior Project Engineer at MiMedx Group in Tampa, FL a biomedicalbased orthopedics and wound care company that is developing combinatorial products that include collagen and polymerbased nanoparticles. She is serving as a reviewer of several reputed journals like Food and Chemical Toxicology, Nanomedicine: Nanotechnology, Biology, and Medicine, Journal of Applied Polymer Science, Recent Patents on Inflammation Allergy Drug Discovery, and Journal of Controlled Release.

Dr. Greenhalgh´s research interest include development of polyacrylate-based nanoparticles for application in wound care, infectious disease, general surgery, and cardiology. She has developed multiple collagen-nanoparticle formulations and has prototyped over 20 different artificial vessels using her patented technology. Interests also include treatment of infectious diseases and cancer with drug conjugated nanoparticles and has had at least 3 funded projects in this area.

Dr. Yan has extensive research experience in biomedical informatics, including more than 10 years as a group leader in the biopharmaceutical industry. Dr. Yan has published many research papers and edited four biomedical books, including "Systems Biology in Drug Discovery and Development: Methods and Protocols" and "Pharmacogenomics in Drug Discovery and Development". Dr. Yan received a PhD degree in Biological and Medical Informatics from the University of California San Francisco (UCSF).

Bioinformatics, health informatics, medical informatics, systems biology, pharmacogenomics, personalized medicine, immunology, neuroscience, immunoinformatics, neuroinformatics, translational medicine, drug design, drug discovery.

She currently holds Faculty appointments and Graduate appointments in the UK College of Pharmacy, Graduate Faculty at UNC-Chapel Hill, Dr. Mansour is an active long-time member of several professional organizations,. In addition to being an Editorial Advisory Board EAB member of JNMNT, she serves on the EAB of other journals including Pharmaceutical Technology and the International Research Journal of Pharmaceutical Sciences. She also serves as UK COP Delegate to the United States Pharmacopeia USP and on the International Scientific Expert Committee of the World Academy of Science, Engineering, and Technology WASET. She serves as an expert reviewer of over 25 scientific journals and has published journal articles, book chapters, and international meeting abstracts. Dr Mansour has given many invited speaker presentations.

Mansours research focuses on the application of Nanomedicine/Nanoimaging, colloidal self-assemblies, Targeted multifunctional particulate delivery, Nanoliposomal drug delivery, Nanoliposomal biophysics, Controlled release drug delivery, Pulmonary delivery systems, and Nanoaerosol science.

He got his PhD in Molecular Biophysics From University of Leeds, 1992. He is an innovative specialist in bioinformatics, computational chemistry, and cheminformatics, with unique experience of the preclinical research environment in both academia and the pharmaceutical industryand a world leader in the area of Immunoinformatics, the application of informatics techniques to immunological biomacromolecules and immune systems.His experience includes a PhD in Structural Biology.

His initial research objectives lie at the intersection of drug design and immunology, In the field of Immunoinformatics, in silico, in vitro, and in vivo discovery of novel small-molecule adjuvants; epitope identification leveraging a range of techniques; and also the discovery of novel whole protein antigens as candidate vaccines and bioinformatics, cheminformatics, and the molecular dynamic simulation of semi-stochastic systems.

Dr. Walsh is Reader (Associate Professor) in Inflammation & Immunity and Principal Investigator, of the Asthmatic & Allergic Inflammation Group, School of Medicine & Dentistry, University of Aberdeen, UK. His group is part of the Immunology Research Programme, within the Division of Applied Medicine that was rated fourth equal in the UK in the 2008 research assessment exercise. Dr Walsh is honorary Professor of Inflammation & Immunity, School of Medicine, Trinity College, Dublin, Ireland. His major research interests involve elucidation of the molecular mechanisms controlling the initiation and resolution of the inflammatory processes underlying asthma, COPD and allergic disease. Dr Walsh has published over 60 peer-reviewed articles in international journals together with more than 90 invited editorials, reviews and book chapters.  To date these publications have been cited over 3,800 times; giving an h-index of 33 (source ISI Web of Knowledge). Dr Walsh has been an invited speaker and/or chairman at over fifty international meetings. In addition to his role as the Editor-in-Chief of Therapeutics and Clinical Risk Management he is the Founding Editor of the Journal of Cell Death; and Clinical Medicine - Therapeutics. He is also an Editorial Board Member of the Journal of Allergy (Section Head), International Journal of Biomedical Science, Biologics: targets and therapy, The Open Immunology Journal, The Open Inflammation Journal, The Open Allergy Journal and the Journal of Organ Dysfunction. Dr Walsh is a regular reviewer for over 40 clinical and scientific journals and serves as a grant reviewer for UK and international funding bodies. Since 2003 he has been a European Commission evaluation expert for FP6 and FP7 and is currently Vice-Chair of the Evaluation Panel for Marie Curie Reintegration Mobility Actions. Dr Walsh was a Member of the MRC College of Experts affiliated to the Infection and Immunity Board and a Member of Lung Cellular and Molecular Immunology (LCMI) Special Emphasis Panel, National Institutes of Health USA.
 

Dr. Dell′Orco studied Physics and Biophysics at the University of Parma Italy and Lund Sweden. He obtained a PhD in Biotechnology and Molecular Medicine from the University of Modena and Reggio Emilia Italy. During his activity he visited several laboratories in Sweden and in Germany. He is currently A. von Humboldt Research Fellow at the University of Oldenburg Germany. On a regular basis he acts as a referee for several peerreview journals in the fields of Biochemistry, Biophysical Chemistry and Systems Biology.

The main scientific activity of Dr. Dell′Orco is focused on the experimental and theoretical characterization of protein-protein and protein-ion interactions involved in vertebrate vision. This includes systems biology approaches to unravel the biochemical mechanisms behind complex cell behaviors in photoreceptors during normal and disease-associated conditions. He is also involved in the computational analysis of nanoparticle-protein interactions in several biologic fluids and the perturbations exerted by nanopaticle-protein complexes on biochemical processes.

He received his Master Degree in Biology specialization:Biotechnology PhD in Innovative Health Technologies. He works in a multidisciplinary and international group of chemical and biomedical engineers, biologists and physicists. He worked for the European project “NINIVE” Non invasive nanotransducer for in vivo Gene Therapy He works in a multidisciplinary and international group of chemical and biomedical engineers, biologists and physicists.

Research activity in nano-biomedical technologies. Molecular and cellular techniques:In vitro propagation, transfection and transduction of adherent and suspension cell lines. In vitro cytotoxicity studies (MTT, WST-1, Annexine apoptosis assay, Oxidative Stress assay) about artificial nanovectors and their interaction with cells . Several molecular biology (PCR, RT-PCR, quantitative real-time PCR TaqMan) techniques for gene cloning in plasmid, lentiviral and artificial vectors, microbiology and proteomic techniques ( Immunostaining, Western blotting, Flow cytometry). In vitro cell transfection by electroporation with carbon nanotubes and lipofectamine methods.

I was born in Lvov city (USSR) January 14, 1953.Graduated Chemical Department of Moscow State University (MSU) in 1975. In 1980 defended PhD dissertation and in 1993 defended the Doctor of science degree dissertation in (biochemistry). Professor in “Bioorganic chemistry”. In 2003 was elected as a personal member of Russian Academy of Sciences. From 1981 till the present time I am working in the Institute of Physiologically Active Compounds Russian Academy of Sciences (IPAC RAS). From 1991 till the present time I am the Head of the Department of Medicinal and Biological Chemistry. From 1986 till 2006 was Deputy Director in Science, and science 2006 is the Director of the IPAC RAS. I was invited scholar in the University of California, San Francisco, USA (1992) and in Tufts University School of Medicine, Boston, USA (1995). The Chairman of Moscow Branch of the Russian Chemical Society, Titular member of the IUPAC (Division “Chemistry and Human Health”). The Editorial Board Member of the journals: “Uspekhi Khimii (Advances in Chemistry)” of Russian Academy of Sciences (russ), “Izvestia (News) of Academy of Sciences: Chemical series” (russ), "Recent Patent Reviews on CNS Drug Discovery" and “Open Toxicology Journal” (Bentham Science Publishers Ltd.). Last 5 years I was the Principal Investigator of 7 international and more than 20 Russian grants. The author more than 150 publications, and about 30 patents.

Drug design and Drug discovery. Medicinal chemistry of neurodegenerative disorders, in particular, Alzheimers disease, Parkinsons disease. Mechanism-based search for new medicines for neurological disorders, in particular, neuroprotectors and cognition-enhancers. Experimental models of neurological disorders. Novel drug-delivery system, in particular synthetic nanosized particles as a drug-delivery agents. 

Dr. Rui Liu is a lecturer in College of Traditional Chinese Medicine, Tianjin University of Traditional Chinese Medicine, China. In recent years, more scientific projects have been presided and participated. University Education Science and Technology Development Fund Program of Tianjin (Project Name: Research on Curcumin Ocular Delivery System Based on Corneal Permeability Enhancing, No. 20110215) was presided. Ministry of Science and international cooperation project (Project Name: Application research on modern preparation technique in traditional Chinese preparation, No. 2007DFC31670) was participated as the principal completer. National Natural Science Foundation of China (Project Name: Research on brain targeting drug delivery system of monoclonal antibody OX26 of PEG-modified cationic nanoparticles of baicalin, No. 81001645) was participated as the leading researcher. More than 10 papers have been published in Chinese and international journals, including 3 SCI papers.

Nanoparticles and Microparticles in Drug Delivery
Ocular Drug Delivery
Transdermal Drug Delivery
Absorption enhancer screening
Osmotic Pump Delivery System

Joaquin Sanchis-Martinez obtained his PhD in Organic Chemistry in 2005 from the University of Valencia (Spain), after being graduated in Chemistry at the same University. After his doctoral degree, he held a contract research position at BASF AG (Germany). Afterwards, he joined Max-Planck-Institut (Germany) as a post-doctoral researcher focusing his work on Biocatalysis and Enzyme Engineering by directed evolution.  Currently, he is developing polymer-drug conjugate nanomedicines with application in the treatment of cancer and Regenerative Medicine at the Polymer Therapeutics lab in the Biomedical Research Center Principe Felipe in Valencia. In addition, he is a part-time associate lecturer at the Faculty of Chemistry in the University of Valencia.

He is involved in the design of antiangiogenic and cytotoxic nanocompounds based on water-soluble and biocompatible polymers for systemic delivery in cancer combination therapy. He is also interested in the development of smart polymer-drug conjugates and composites for tissue regeneration.

Small molecule (oligopeptides) identification for biotherapeutic discovery and studying their role in (patho)physiology using system biology and pharmacology approach.

Dmitri V. Krysko graduated with greatest distinction from Saratov State Medical University in Russia in 1998. In 2000 he moved to Belgium, where in 2006 he obtained a Ph.D. degree in Medical and Health Sciences from Ghent University. In 2006 he became a laureate of the Annual Belgian Society for Microscopy Award in Life Sciences for the “Outstanding PhD thesis”. Dr Krysko then obtained a postdoctoral scholarship from The Research Foundation-Flanders (FWO, Belgium). He is currently working as a senior FWO postdoctoral scientist in the Molecular Signalling and Cell Death Unit at the Department for Molecular Biomedical Research in VIB-Ghent University (Belgium). Dr Krysko is leading a subgroup investigating how dying cells (apoptotic, necrotic and autophagic) interact with innate and adaptive immune system by means of Damage-Asscociated Molecular Patterns (DAMPs).Dr Krysko is an Editorial Board Member of “Apoptosis: An International Journal on Programmed Cell Death,Mediators of Inflammation and “Frontiers in Molecular Innate Immunity” Dr. Krysko was a co-quest editor of a special issue of Apoptosis (“Clearance of dead cells: mechanisms, immune responses and implication in the development of diseases;” 2010; 15; 995-1164) and a co-editor of a book (“Phagocytosis of dying cells: from molecular mechanisms to human diseases;2009 Springer.

The major scientific interest of Dr. Dmitri V. Krysko is a comparative analysis of how cells dying by different cell death modalities (apoptotic, necrotic and autophagic) interact with innate and adaptive immune system by means of damage-associated molecular patterns (DAMP).

Paul currently works as a Lecturer in the Department of Chemistry at Kasetsart University.  He is a Principal Investigator in Cheminformatics/Molecular Modelling, has 2 Supervises 2 PhD students and acts as an advisor for over 5 more. He also plays a coordination role in drug discovery efforts at the Chulabhorn Research/Graduate Institute, in a joint project to discover novel Glycogen Synthase Kinase leads, with good potency and developability characteristics. 

Molecular modelling, Cheminformatics, ADMET, QSAR.

He received his PhD in 2003 from Central electrochemical research institute, chennai,(university of madras). He completed his post doctorial felllowship inbetween 2003 - 2004 (1 year), in Department of chemistry, graduate school of sciences,Tohoku university, sendai, japan. He Selected as the research professor by kbsi, busan, south korea. He is currently working as Associate Professor in Department of Organic Chemistry, School of Advanced Sciences, VIT- University, India.

Organic synthetic methodologies, Different types of reactions involving -simple catalysis-reduction, oxidation, cyclisation, condensation, moisture sensitive Grignard reactions, allylations, N-arylations, periodate oxidations, sodium borohydride reactions, cyclization, Diels alder reaction, Phase transfer reactions, Friedlander reaction, Pfzinger reaction, Fischer indole réaction, Heck reactions, Buckwald coupling etc., Carrying out different types of reactions invoving - chemical, conventional and nonconventional conversions- microwave assisted reactions, named reactions, Nanomaterials in catalysis, Organic synthesis, natural product chemistry, heterocyclics including -Isocoumarins, Isocarbostyrils, isoquinolinone, isoquinolines, quinolines and the S, Se, Te analogues. Also including thiazoles, pyrazoles, triazoles, thiadiazoles, oxazoles,etc., Camptothecin and Mappicine Analogue synthesis- activity studies, Nanomaterials-Nanotubes, nanorods, chiral nanomaterials- synthesis, characterisation and applications, Handling various instruments like NMR, UV, IR spectroscopy and also Gas chromatography and GC-Mass spectroscopy and interpretation of various reactions products and mechanism of reactions, Carrying out different studies - X-Ray diffraction, stereochemical investigation, antibacterial studies, anticancer activity antityroid, antioxidant, anti-inflammatory and DNA interaction studies
 

Dr. Lingdong Quan currently working as a research scientist in Hospital for Special Surgery and Cornell University.

His research interest is to develop nanotechnology-based drug delivery systems for non-invasive imaging, diagnosis and improved treatment of rheumatoid arthritis, bone fracture healing, implant-associated osteolysis and other musculoskeletal disease.

Dr. Kristina Riehemann studied Biology and Physics at the University of Münster. She spent her postdoctoral time at the Institute of Pathology at the University Hospital Münster and was Junior group leader at the Institute of Medical Biochemistry at the ZMBE (Centre for Molecular Biology of Inflammation) with the research focus "Anti-inflammatory mechanisms". After coordination and managing the “Integrated functional Genomics (IFG)”, a service unit of the “Interdisciplinary center of clinical research” (IZKF) she moved as aheadof the nanobio service lab at the Center for Nanotechnology (CeNTech) where she coordinatesseveral BMBF funded german-chinese,german-korean as well as academic/industrial collaboration projects.

Anti-inflammatory mechanisms
Physical property of cells
Nanoanalytical techniques applied on cells 
characterization of cell differentiation/activation

Dr. Gomez received his B.S. in Chemistry with departmental honors from Cal State L.A. in 1986 and his Ph.D. in Chemistry from UCLA in 1991. From 1991-1994 he was a Postdoctoral Fellow in Chemistry at Harvard University. He is Professor of Chemistry at Cal State L.A. He has published over 90 articles, nine book chapters and two books on his research. He and his students have delivered over 200 conference presentations.

His research group is engaged in developing fundamental and applied research in the area of microfluidics and capillary electrophoresis (CE). In microfluidics, focus is on developing new microfluidic devices (MDs) for use in chemical and biochemical separations and point-of-care (POC) diagnostics. Current work involves the development of bead-based assays, surface plasmon resonance (SPR)-CE on chips, microfluidic direct methanol fuel cells (?DMFCs), novel materials for microfluidics, chromatography on chips, hyphenated techniques, and affinity capillary electrophoresis (ACE). In CE, focus is on developing new methodologies associated with ACE, and enzyme microreactors. Response surface methodology (RSM) and artificial neural networks (ANN) are also employed to experimentally optimize conditions in several microfluidic and CE applications.

I am responsible for leading nano safety research with the aim of identifying whether a variety of nanoparticles, objects, devices and medicines can enter the human body, interact with the respiratory, immune and reproductive systems and cause harm. My primary research interests include nanotoxicology and reproductive biology. The focus of this work is to investigate the effects of environmental pollutants, including nanoparticles, on the developing foetus and male reproductive health and fertility. This work involves the development of in vitro and in vivo models to assess the safety of various chemicals and nanoparticles in relation to endocrine disruption, reproductive and developmental health. As an MRC Career Development Fellow I coordinated a program of work examining the effects of phthalate exposure during pregnancy and subsequent toxicological effects on fetal reproductive development. I have secured and contributed to large collaborative nanotoxicology studies such as the EU FP7 projects ENPRA and ENRHES (completed), and MARINA (ongoing). My nanotoxicology research has also been supported by charities (European Respiratory Society, Welcome Trust, Carnegie Trust and Nuffield Foundation), Government (Knowledge Transfer Partnership, Scottish Funding Council, DEFRA), and industry (GlaxoSmithKline).

Nanocarrier mediated targeted drug delivery against chronic infection and cancer
Image guided therapy, Nanotoxicology

Krishnan received his medical degree from  Christian Medical College, Vellore, India and completed an internal medicine residency at Penn State Geisinger Medical Center, Danville, Pennsylvania followed by a radiation oncology residency at Mayo Clinic, Rochester, Minnesota. He is currently a tenured associate professor of radiation oncology at MD Anderson Cancer Center. His clinical focus is on treatment of gastrointestinal cancers. His laboratory focus is on integrating tumor-specific targeting, image-guidance and radiosensitizing approaches using conjugated nanoparticles. He has served as the chair of the gastrointestinal scientific program committee of ASTRO, the co-chair of the gastrointestinal translational research program of RTOG, councilor for the Society for Thermal Medicine, and consultant to IAEA. He co-chairs the biology wing of the Center for Radiation Oncology Research at MD Anderson Cancer Center.

Integrating tumor-specific targeting, image-guidance and radiosensitizing approaches using conjugated nanoparticles